BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Up 32.5% in April

BioLineRx Ltd. (NASDAQ:BLRX) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 783,600 shares, a growth of 32.5% from the March 31st total of 591,500 shares. Based on an average daily trading volume, of 432,700 shares, the short-interest ratio is currently 1.8 days.

BioLineRx Price Performance

NASDAQ:BLRX traded up $0.04 during trading hours on Friday, reaching $0.61. 582,908 shares of the company were exchanged, compared to its average volume of 620,553. The company has a current ratio of 1.53, a quick ratio of 1.47 and a debt-to-equity ratio of 0.50. BioLineRx has a twelve month low of $0.55 and a twelve month high of $2.53. The firm has a market cap of $48.89 million, a PE ratio of -0.68 and a beta of 1.38. The stock’s 50-day moving average is $1.01 and its 200-day moving average is $1.30.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. The business had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $0.17 million. During the same period last year, the business earned ($0.09) earnings per share. On average, sell-side analysts anticipate that BioLineRx will post -1.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BLRX has been the topic of several recent research reports. StockNews.com upgraded shares of BioLineRx to a “sell” rating in a research report on Tuesday, April 23rd. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of BioLineRx in a report on Wednesday, April 17th.

Institutional Investors Weigh In On BioLineRx

Institutional investors and hedge funds have recently modified their holdings of the stock. NorthRock Partners LLC purchased a new stake in BioLineRx in the 4th quarter worth approximately $27,000. B. Riley Wealth Advisors Inc. lifted its holdings in BioLineRx by 88.5% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 10,000 shares during the last quarter. Allen Mooney & Barnes Investment Advisors LLC acquired a new position in shares of BioLineRx in the 3rd quarter worth approximately $46,000. Rathbones Group PLC bought a new stake in shares of BioLineRx during the third quarter worth $72,000. Finally, Values First Advisors Inc. bought a new stake in BioLineRx during the 3rd quarter worth about $88,000. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.